Fortrea Holdings Inc. (NASDAQ: FTRE) is a Healthcare company (Biotechnology) with a market capitalization of $1.9B. The Maz Rating grades it against the other companies in its sector.
Fortrea Holdings Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $19.59, Fortrea Holdings Inc. trades at 0.7x sales and 3.5x book value, with an EV/EBITDA of 26.4. Over the last twelve months it generated about $2.7B of revenue and a net loss of $71M. It runs a gross margin of 18.5%, an operating margin of 1.6% and a net margin of -2.6%. It shows return on equity of -12.8%, return on invested capital of 2.3% and a free cash flow yield of 6.7%. On the balance sheet: a debt-to-equity ratio of 2.10 and a current ratio of 0.97. Over the past 52 weeks the share price ranged from $8.55 to $26.16, with a beta of 1.86.
Fortrea Holdings Inc. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 7 Buy, 5 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Fortrea Holdings Inc. (FTRE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 55.2% / 30% · (Cash+Inv) / Mkt Cap (36m) 11.5% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 55.2% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 11.5% / 33% · Receivables / Mkt Cap (36m) 33.5% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 55.2% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 11.5% / 33.33% · Receivables / Mkt Cap (24m) 33.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 38.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 6.55% / 33.33% · Receivables / Avg Assets (4Q) 23.4% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 38.5% / 33.33% · (Cash+ST Inv) / Total Assets 8.06% / 33.33% · (Cash+Recv) / Total Assets 31.5% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, Fortrea Holdings Inc. (FTRE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Fortrea Holdings Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
Fortrea Holdings Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.